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Background: This study tested the hypothesis that exendin-4 and sitagliptin can effectively protect kidney from
acute ischemia-reperfusion (IR) injury.
Methods: Adult SD-rats (n = 48) equally divided into group 1 (sham control), group 2 (IR injury), group 3 [IR + sitagliptin
600 mg/kg at post-IR 1, 24, 48 hr)], and group 4 [IR + exendin-4 10 μm/kg at 1 hr after procedure] were sacrificed after
24 and 72 hrs (n = 6 at each time from each group) following clamping of bilateral renal pedicles for 60 minutes
(groups 2–4).
Results: Serum creatinine level and urine protein to creatinine ratio were highest in group 2 and lowest in group 1
(all p < 0.001) without notable differences between groups 3 and 4. Kidney injury score, expressions of inflammatory
biomarkers at mRNA (MMP-9, TNF-α, IL-1β, PAI-1), protein (TNF-α, NF-κB and VCAM-1), and cellular (CD68+) levels in
injured kidneys at 24 and 72 hr showed an identical pattern compared to that of creatinine level in all groups
(all p < 0.0001). Expressions of oxidized protein, reactive oxygen species (NOX-1, NOX-2), apoptosis (Bax, caspase-3
and PARP), and DNA damage marker (γH2AX+) of IR kidney at 24 and 72 hrs exhibited a pattern similar to that of
inflammatory mediators among all groups (all p < 0.01). Renal expression of glucagon-like peptide-1 receptor, and
anti-oxidant biomarkers at cellular (GPx, GR) and protein (NQO-1, HO-1, GPx) levels at 24 and 72 hr were lowest in
group 1, significantly lower in group 2 than in groups 3 and 4 (all p < 0.01).
Conclusion: Exendin-4 and sitagliptin provided significant protection for the kidneys against acute IR injury.
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Acute kidney injury (AKI) is a commonly encountered
complication in hospitalized patients and significantly
contributes to morbidity and mortality [1-5]. Recent
studies have further demonstrated that AKI was evident
in around 20% of patients who died in hospitals and up to
50% of patients in the intensive care unit (ICU) [6,7]. The* Correspondence: han.gung@msa.hinet.net
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reproduction in any medium, provided the oretiology of AKI is multifactorial [1-12]. Among the various
etiologies of hospital-acquired AKI, ischemia-reperfusion
(IR) injury is the leading cause of AKI [13-15] that is asso-
ciated with a high mortality rate [16,17]. The causes of
acute kidney IR injury are divergent, including contrast
media-induced nephropathy [9,18], shock followed by
resuscitation in the emergency and intensive care settings
[11,19], kidney transplantation [20,21], sepsis [22], and
cardiovascular surgery [23].
Previous studies [11,15,23-27] have reported that the
underlying mechanisms of acute kidney IR injury are
mainly through the generation of oxidative stress and
reactive oxygen species (ROS), rigorous inflammatory
reaction, and enhancement of cellular apoptosis aftertd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mental studies have further revealed that inhibition of
inflammatory reaction and suppression of the generations
of pro-inflammatory cytokines and oxidative stress using
immuno- or pharmaco-modulation significantly protect
the kidney from acute IR injury [23-27].
Glucagon-like peptide-1 (GLP-1)-based pharmaceuticals
are emerging as potent regimens against type 2 diabetes
mellitus (T2DM). Exendin-4 and liraglutide, two GLP-1
analogues, have been reported to have multiple cellular
protective effects, including the protection of endothelial
cells against senescence mainly through anti-oxidative
[29-31] and anti-inflammatory [31-33] processes. Addition-
ally, studies have revealed that GLP-1 mediates in the thera-
peutic actions of dipeptidyl peptidase (DPP)-IV inhibitors
[34]. Interestingly, sitagliptin, currently used for treating
type 2 diabetic patients, has been found to be able to
enhance circulating GLP-1 levels through inhibition of
DPP-IV activity [35,36] which, in turn, provides cardiovascu-
lar protective effect probably through the anti-inflammatory
and anti-atherosclerotic actions of GLP-1 [37]. Thus, it is
rational to hypothesize that the inflammatory reaction and
oxidative stress from acute renal IR injury may be alleviated
by either Exendin-4 (i.e., GLP-1 analogue) or sitagliptin




All animal experimental procedures were approved by the
Institute of Animal Care and Use Committee at Kaohsiung
Chang Gung Memorial Hospital (Affidavit of Approval
of Animal Use Protocol No. 2008121108) and performed
in accordance with the Guide for the Care and Use of
Laboratory Animals (NIH publication No. 85–23, National
Academy Press, Washington, DC, USA, revised 1996).
Animal grouping and induction of acute kidney
ischemia-reperfusion injury
Pathogen-free, adult male Sprague–Dawley (SD) rats
(n = 48) weighing 320–350 g (Charles River Technology,
BioLASCO Taiwan Co. Ltd., Taiwan) were randomized
and equally divided into group 1 (sham controls, n = 12),
group 2 (acute kidney IR injury only, n = 12), group 3
(sitagliptin 600 mg/kg orally at post-IR 1, 24, and 48 hr),
and group 4 (IR + sitagliptin 600 mg/kg orally + exendin-4
10 μm/kg subcutaneous injection at post-IR 1 hr). The
rats were sacrificed at post-IR 24 hr (3 hrs after sitagliptin
treatment) and 72 hr (n = 6 each time for each group) for
determining the therapeutic effects of sitagliptin and
exendin-4 at acute (i.e., 24 hr) and subacute (i.e., 72 hr)
phases of IR injury.
All animals were anesthetized by inhalational 2.0%
isoflurane, placed supine on a warming pad at 37°C formidline laparotomies. Sham-operated rats (group 1)
received laparotomy only, while acute IR injury of both
kidneys were induced in all animals in groups 2 to 4 by
clamping the renal pedicles for one hour using non-
traumatic vascular clips. The rats were sacrificed at 24
and 72 hrs (n = 6 at each time from each group) after IR
procedure. The kidneys were harvested for individual
study.
Rationale of drug dosage for the study
To elucidate relatively suitable drug dosages for the present
study, acute kidney IR injury in four additional rats
was treated by either a low (n = 2) or a high (n = 2)
dose of sitagliptin (i.e., 200 or 600 mg/kg/day for three
days, respectively). Similarly, four other rats were
treated with either a low (n = 2) or a high (n = 2) dose
of exendin-4 six (i.e., 5 or 10 μg/kg once, respectively) after
renal IR induction. Immunohistochemical (IHC) staining
and the protein expressions of GLP-1R in kidney paren-
chyma were notably higher in the rats treated with a high
dose of sitagliptin or exendin-4 compared with those re-
ceiving low doses of the two drugs. Thus, 600 mg/kg/day
of sitagliptin for three successive days and 10 μg/kg (single
dose only) of exendin-4 were utilized in the current study.
To elucidate the possible GLP-1-mediated therapeutic
effect of sitagliptin against acute kidney IR injury, the
circulating level of GLP-1 was measured in each animal.
In addition, eight additional SD rats were equally divided
into: 1) sham control, 2) IR only, 3) IR + sitagliptin
600 mg/kg (orally, 1 hr after acute kidney IR), 4) IR + sita-
gliptin 600 mg/kg + exendin-9-39 (an inhibitor of exendin-4)
10 μm/kg at 1 hr after the procedure. The animals were
sacrificed at 24 hr after acute kidney IR. The kidney was
collected in each animals for specific study (please see the
results of Figure 1).
Assessment of circulating GLP-1 level and renal function
before and after IR procedure
Serum GLP-1, creatinine, blood urea nitrogen (BUN), urine
protein, and urine creatinine levels were determined in
all animals before and after (at 24 and 72 hours) the IR
procedure prior to their sacrifice. Quantification of GLP-1
level, BUN, serum and urine creatinine, and urine protein
levels was performed using standard methods according
to manufacturers’ instructions.
Collection of 24-hour urine before and after
(on days 1 and 3) IR procedure
For the collection of 24-hr urine for individual study, each
animal was put into the animal's metabolic cage [DXL-D,
space: 190 × 290 × 550; shu-sz.com, Mainland China] for
24 hrs with food and water supply. Urine in 24 hr was
collected in all animals prior to the IR procedure and at
24 hr and 72 hr after reperfusion prior to their sacrifice
Figure 1 Immunohistochemical (IHC) and H.E. staining and Western blot for determining the impact of sitagliptin and exendin-9-39
effect on acute kidney ischemia-reperfusion (IR) injury at 24 h after IR procedure. A to D) The H.E stain (200 x) showing notably higher
acute kidney injury score, including: brush border in renal tubules (yellow arrowheads), cast formation (green asterisk), tubular dilatation
(blue asterisk), tubular necrosis (green arrows), and dilatation of Bowman’s capsule (blue arrows) in ischemia reperfusion (IR) only and
IR + sitagliptin (Sita) + exendin (Ex)-9-39 animals than in IR + sitagliptin animals. E to H) The immunohistochemical (IHC) stain (200 x)
demonstrating higher expression of glucagon-like peptide-1 receptor (GLP-1R) (brown color staining) in IR animals with sitagliptin +
exendin-9-39 treatment and further higher expression of this biomarker than in RI only animals in renal parenchyma. Very few expression of
GLP-1R in normal kidney parenchyma (E) was observed. Scale bars in right lower corner represent 50 μm. I) The protein expressions of
ADPH oxidase (NOX)-1, NOX-2, intercellular adhesion molecule (ICAM)-1, tumor necrotic factor (TNF)-α, nuclear factor (NF)- κB, matrix
metalloproteinase (MMP)-9, and J) oxidized protein were remarkably higher in IR and IR + sitagliptin + exendin-9-39 animals than in
IR + sitagliptin animals.
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protein to urine creatinine.
Histopathology scoring and immunofluorescent (IF)
staining at 24 and 72 hr after the IR procedure
Histopathology scoring was determined in a blinded
fashion as we previously reported [24]. Briefly, the kidney
specimens from all animals were fixed in 10% buffered
formalin, embedded in paraffin, sectioned at 5 μm and
stained (hematoxylin and eosin; H&E) for light microscopy.
The scoring system reflecting the grading of tubular
necrosis, loss of brush border, cast formation, and tubulardilatation in 10 randomly chosen, non-overlapping fields
(200x) was as follows: 0 (none), 1 (≤10%), 2 (11–25%), 3
(26–45%), 4 (46–75%), and 5 (≥76%) [24].
The IF methodology used in this study have recently
been described in details [24]. The IF staining methodology
was used for the examination of CD68+ cells (an indicator
of macrophage) using respective primary antibodies.
Western blot analysis of kidney specimens
Equal amounts (10–30 μg) of protein extracts from ische-
mic kidneys of the animals (n = 10 for each group) were
loaded and separated by SDS-PAGE using 7% or 12%
Chen et al. Journal of Translational Medicine 2013, 11:270 Page 4 of 19
http://www.translational-medicine.com/content/11/1/270acrylamide gradients. The membranes were incubated
with monoclonal antibodies against GLP-1R (1:1000,
abcam), matrix metalloproteinase (MMP)-9 (1:1000,
Millipore), intercellular adhesion molecule (ICAM)-1 (1:
2000, Abcam), NAD(P)H quinone oxidoreductase (NQO) 1
(1: 1000, Abcam), heme oxygenase (HO)-1 (1: 250,
Abcam), Glutathione peroxidase (GPx) (1:2000, abcam),
and polyclonal antibodies against tumor necrosis factor
(TNF)-α (1: 1000, Cell Signaling), nuclear factor (NF)-κB
(1:600, Abcam), ADPH oxidase (NOX)-1 (1:1500, Sigma),
NOX-2 (1:500, Sigma), Bax (1: 1000, Abcam), caspase 3
(1: 1000, Cell Signaling), poly(ADP-ribose) polymerase
(PARP) (1: 1000, Cell Signaling), Bcl-2 (1:250, Abcam),
catalase (1:1000, abcam), superoxide dismutase 1 (SOD-1)
(1:2000, abcam), γH2AX (1:1000, Cell signaling), and
endothelial nitric oxide synthase (eNOS) (1:1000, Abcam)
were used. Signals were detected with horseradish pero-
xidase (HRP)-conjugated goat anti-mouse, goat anti-rat,
or goat anti-rabbit IgG.
The Oxyblot Oxidized Protein Detection Kit was pur-
chased from Chemicon (S7150). The procedure of 2,4-dini-
trophenylhydrazine (DNPH) derivatization was carried
out on 6 μg of protein for 15 minutes according to the
manufacturer’s instructions. One-dimensional electrophor-
esis was carried out on 12% SDS/polyacrylamide gel after
DNPH derivatization. Proteins were transferred to nitro-
cellulose membranes which were then incubated in the
primary antibody solution (anti-DNP 1: 150) for two hours,
followed by incubation with the second antibody solution
(1:300) for one hour at room temperature. The washing
procedure was repeated eight times within 40 minutes.
Immunoreactive bands were visualized by enhanced
chemiluminescence (ECL; Amersham Biosciences), which
was then exposed to Biomax L film (Kodak). For quantifi-
cation, ECL signals were digitized using Labwork software
(UVP). For oxyblot protein analysis, a standard control
was loaded on each gel.Real-time quantitative PCR analysis
The mRNA expressions of TNF-α, interleukin (IL)-1β,
MMP-9, plasminogen activator inhibitor (PAI), IL-10,
and endothelial nitric oxide synthase (eNOS) in each of
the four groups of animals were analyzed with RT-qPCR
and compared.Statistical analysis
Quantitative data are expressed as means ± SD. Statistical
analyses were performed using SAS statistical software for
Windows version 8.2 (SAS institute, Cary, NC) to conduct
ANOVA followed by Bonferroni multiple-comparison
post hoc test. A probability value <0.05 was considered
statistically significant.Results
Exendin-9-39 inhibited the effect of sitagliptin on
attenuating the acute kidney IR injury (Figure 1)
To assess the effect of sitagliptin therapy on ameliorating
acute kidney IR was inhibited by extendin-9-39, an antag-
onist of exendin-4, 24 hr acute kidney IR injury was done
in additional six animals, i.e., IR only (n = 2), IR + sitagliptin
(n = 2), and IR + sitagliptin + exendin-9-39. The H. & E.
stain showed that as compared with IR only, sitagliptin
therapy markedly reduced the kidney injury score.
However, this treatment effect was notably reduced by
extendin-9-39. Additionally, the expression of GLP-1R in
kidney parenchyma was notably higher in sitagliptin-
treated animals than in those of IR only animals. However,
the treatment effect was remarkably diminished by exten-
din-9-39 treatment. Moreover, the protein expressions of
oxidative stress (oxidized protein), ROS (NOX-1, NOX-2),
and inflammatory biomarkers (ICMA-1, TNF-α, NF-κB,
MMP-9) were markedly lower in sitagliptin-treated
animals than in IR only animals. However, despite of
the sitagliptin treatment, these protein expressions were
up-regulated again by extendin-9-39 therapy in the
acute kidney IR animals. Furthermore, after acute kid-
ney IR injury, the circulating level of GLP-1 was signifi-
cantly higher animals than in other groups of the animals
(Figure 2-L, 2-M). Accordingly, our findings supported
that the effect of sitagliptin therapy on attenuating acute
kidney IR injury was mainly through regulating the
circulating level of GLP-1, a signaling pathway similar
to exedinin-4.Changes in renal functions and circulating levels of GLP-1
at 24 h and 72 h after acute renal IR injury (Figure 2)
Prior to the IR induction, the serum levels of BUN and
creatinine were similar among the sham controls (group
1), animals with IR injury only (group 2), IR injury + sita-
gliptin (group 3), and IR injury + exendin-4 (group 4).
However, at 24 hr after reperfusion, the serum levels of
BUN and creatinine were significantly higher in group 2
than those in other groups and significantly higher in
groups 3 and 4 than those in group 1, but it showed no
difference between groups 3 and 4. In addition, at 72 hr
after IR procedure, these two parameters showed an
identical pattern compared to that of 24 hr among the
four groups.
The daily urine amount and the ratio of urine pro-
tein to urine creatinine prior to the IR procedure did
not differ among the four groups. However, the daily
urine amount was significantly less in group 2 than
that in other groups and significantly less in group 1
than groups 3 and 4, and significantly less in group 3
as compared to that of the group 4 at 72 hr after
reperfusion.
Figure 2 (See legend on next page.)
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Figure 2 Serum levels of blood urea nitrogen (BUN), creatinine and glucagon-like peptide-1 (GLP-1), urine amount and ratio of urine
protein to creatinine after ischemia-reperfusion (IR) procedure (n = 6 at each time for each group). A) Baseline serum BUN level;
p value >0.5 among the four groups. B) Serum level of BUN at 24 h after IR procedure; * vs. other groups with different symbols, p < 0.001.
C) Serum level of BUN at 72 h after IR procedure; * vs. other groups with different symbols, p < 0.001. D) Baseline serum creatinine level; p value
>0.5 among the four groups. E) Serum level of creatinine at 24 h after IR procedure; * vs. other groups with different symbols, p < 0.001. F) Serum
level of creatinine at 72 h after IR procedure; * vs. other groups with different symbols, p < 0.001. G) Baseline urine amount; p value >0.5 among
the four groups. H) Urine amount at 72 h; * vs. other groups with different symbols, p < 0.001. I) Baseline ratio of urine protein to creatinine; p
value >0.5 among the four groups. J) Ratio of urine protein to creatinine at 27 after IR procedure; * vs. other groups with different symbols,
p < 0.005. K) Baseline serum concentration of GLP-1; p value >0.5 among the four groups. L) Serum concentration of GLP-1 at 24 h after IR
procedure; * vs. other groups with different symbols, p < 0.005. M) Serum concentration of GLP-1 at 72 h after IR procedure; * vs. other groups
with different symbols, p < 0.001. Statistical analysis using one-way ANOVA, followed by Bonferroni multiple comparison post hoc test (n = 6).
Symbols (*, †, ‡) indicate significant difference (< 0.05). SC = sham control; IR = ischemia-reperfusion; Sita = sitagliptin; Ex-4 = extendin-4.
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after IR injury (Figure 3)
To evaluate the therapeutic impact of sitagliptin and
exendin-4 on IR-induced renal injury, histological scoring
based on the typical microscopic features of acute tubularFigure 3 Histopathological scoring of kidney injury at 24 h and 72 h
each group). A to D) and F to I) H. & E. stain (200 x) showing significantly
cast formation (green asterisk), tubular dilatation (blue asterisk), tubular nec
in IR only group than in other groups at 24 h (A to D) and 72 h (F to I) af
groups with different symbols (*, †, ‡, §), p < 0.0001. J) by 72 h after IR proc
All statistical analyses using one-way ANOVA, followed by Bonferroni multip
significance (at 0.05 level). SC = sham control; IR = ischemia-reperfusion; Sitadamage, including extensive tubular necrosis and dilatation,
as well as cast formation and loss of brush border was
adopted. The injury was found to be significantly higher in
group 2 than in other groups, significantly higher in groups
3 and 4 than in group 1 (Figure 3A-E), and significantlyafter ischemia-reperfusion (IR) procedure (n = 6 at each time for
higher degree of brush border in renal tubules (yellow arrowheads),
rosis (green arrows), and dilatation of Bowman’s capsule (blue arrows)
ter IR procedure, respectively. E) by 24 h after IR procedure: * vs. other
edure: * vs. other groups with different symbols (*, †, ‡, §), p < 0.0001.
le comparison post hoc test (n = 6). Symbols (*, †, ‡, §) indicate
= sitagliptin; Ex-4 = extendin-4.
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procedure (Figure 3F-J). These pathological findings might
suggest that on dose of exendin-4 was not inferior to
sitagliptin therapy for protecting acute kidney IR injury.
Changes in mRNA expression of inflammatory and
anti-inflammatory biomarkers in renal parenchyma
at 72 h after IR injury (Figure 4)
The mRNA expressions of TNF-1α, MMP-9, and IL-1β,
three indicators of inflammation, were remarkably higher
in group 2 than those in other groups and significantly
higher in groups 3 and 4 than those in group 1, but it
showed no difference between group 3 and group 4
(Figure 4A-C). Moreover, the mRNA expression of PAI-1,
another indicator of inflammation, was highest in group 2
and lowest in group 1, and significantly higher in group 3
than that in group 4 (Figure 4D). On the other hand, the
mRNA expressions of eNOS and IL-10, two anti-
inflammatory indexes, were highest in group 1 and lowest
in group 2, and significantly higher in group 4 than those
in group 3 (Figure 4E-F).
Expression of glucagon-like peptide-1 receptor (GLP-1R)
in kidney at 24 hr and 72 hr after reperfusion (Figure 5)
IHC staining showed that renal GLP-1R expression was
highest in group 4 and lowest in group 1, and significantly
higher in group 3 than that in group 2 at 24 h (Figure 5A-E)
and 72 h (Figure 5F-I) after the procedure. Additionally, the
protein expression of GLP-1R in the renal parenchyma
showed an identical pattern of IHC staining. These findingsFigure 4 The gene expressions of inflammatory and anti-inflammatory
at each time for each group). A to C) The mRNA expressions of tumor necr
interleukin (IL)-β (C); * vs. other groups with different symbols (*, †, ‡, §), p < 0.
vs. other groups with different symbols (*, †, ‡, §), p < 0.0001. E to F) The mRN
other groups with different symbols (*, †, ‡, §), p < 0.001. All statistical analyses
hoc test (n = 6). Symbols (*, †, ‡, §) indicate significance (at 0.05 level). SC = shasuggest that GLP-1R had an intrinsic ability of an auto-
regulating expression after acute kidney IR injury and an
inversed correlation between the severity of renal IR injury
and GLP-1R expression in renal parenchyma (Figure 5K-L).Renal infiltration of CD68+ cells at 24 and 72 hr
after reperfusion
IF staining demonstrated that the number of CD68+ cells
(i.e., macrophages), an index of inflammation, was highest
in group 2 and lowest in group 1, and significantly higher
in group 3 than that in group 4 at 24 hr or 72 hr after
reperfusion (Figure 6).
The protein expressions of inflammatory, oxidative-stress
biomarkers, and reactive oxygen species (ROS) at 24 and
72 hr after IR injury (Figures 7, 8 and 9).
The protein expressions of TNF-α, NF-κB, and ICAM-1,
three indicators of inflammation, were significantly higher
in group 2 than those in other groups, significantly higher
in groups 3 and 4 than those in group 1 at both 24 h and
72 h after IR procedure. No significant difference in the
expressions of the three parameters, however, was noted
between group 3 and group 4 (Figure 7). Besides, the
protein expressions of NOX-1 and NOX-2, two indices
of ROS, exhibited an identical pattern compared to that of
inflammatory biomarker expressions (Figure 8) among the
four groups at the two time points. Furthermore, the
expression of oxidized protein, an index of oxidative stress,
displayed a pattern similar to that of ROS among the four
groups at the two time points (Figure 9).biomarkers at 72 h after ischemia-reperfusion (IR) procedure (n = 6
otic factor (TNF)-α (A), matrix metalloproteinase (MMP)-9 (B) and
001. D) The mRNA expression of plasminogen activator inhibitor (PAI)-1; *
A expressions of endothelial nitric oxide synthase (eNOS) and IL-10; * vs.
using one-way ANOVA, followed by Bonferroni multiple comparison post
m control; IR = ischemia-reperfusion; Sita = sitagliptin; Ex-4 = extendin-4.
Figure 5 Immunohistochemical (IHC) staining and Western blot analysis of glucagon-like peptide-1 receptor (GLP-1R) at 24 h and 72 h
after ischemia-reperfusion (IR) procedure (n = 6 at each time for each group). A to D) and F to I) The IHC stain (200 x) identifying the
GLP-1R (brown color) in kidney parenchyma among four groups at 24 h (A to D) and 72 h (F to I) after IR procedure, respectively. E) for 24 h
after IR procedure: * vs. other groups with different symbols (*, †, ‡, §), p < 0.0001. J) for 72 h after IR procedure: * vs. other groups with different
symbols (*, †, ‡, §), p < 0.0001. Scale bars in right lower corner represent 50 μm. K and L) The protein expression of GLP-1R in kidney parenchyma
among four group at 24 h (K) and 72 h (L) after acute IR injury, respectively; for 24 h after IR: * vs. other groups with different symbols (*, †, ‡, §),
p < 0.001; for 72 h after IR: * vs. other groups with different symbols (*, †, ‡, §), p < 0.0001. Symbols (*, †, ‡, §) indicate significance (at 0.05 level).
Scale bars in right lower corner represent 50 μm. SC = sham control; IR = ischemia-reperfusion; Sita = sitagliptin; Ex-4 = extendin-4.
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DNA damage markers at 24 and 72 hr after reperfusion
(Figures 10 and 11)
The protein expressions of mitochondrial Bax and
cleaved (i.e., active form) caspase 3 and PARP, three indi-
ces of apoptosis, were significantly higher in group 2 thanthose in other groups, and significantly higher in groups 3
and 4 than those in group 1, but it showed no difference
between groups 3 and 4 at 24 hr and 72 hr after reperfusion
(Figure 10A-F). Conversely, the protein expression of Bcl-2
showed an opposite pattern compared to that of apoptotic
biomarkers after the two intervals of reperfusion (Figure 11).
Figure 6 Immunofluorescent (IF) staining for inflammatory cells (macrophages) at 24 h and 72 after ischemia-reperfusion (IR)
procedure (n = 6 at each time for each group). A to D) and F to I) IF microscopic findings (200 x) showing the number (No.) of CD68+ cell
infiltration (white arrows) in kidney parenchyma among four groups at 24 h (A to D) and 72 h (F to I) after IR procedure, respectively. E) The
analytical results of CD68+ cells in kidney parenchyma at 24 h after IR procedure. * vs. other groups with different symbols (*, †, ‡, §), p < 0.0001.
J) The analytical result of CD68+ cells in renal parenchyma at 72 h after IR procedure. * vs. other groups with different symbols (*, †, ‡, §),
p < 0.0001. Scale bars in right lower corner represent 50 μm. All statistical analyses were with one-way ANOVA followed by Bonferroni multiple
comparison post hoc test. Symbols (*, †, ‡, §) indicate significance at the 0.05 level. SC = sham control; IR = ischemia-reperfusion;
Sita = sitagliptin; Ex-4 = extendin-4.
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cator of DNA damage, was significantly higher in group 2
than that in other groups, and significantly higher in
groups 3 and 4 than that in group 1, but no difference was
noted between groups 3 and 4 at these two time points
(Figure 11A-D).
The protein expressions of anti-oxidative and
anti-inflammatory biomarkers at 24 and 72 hr
after reperfusion (Figures 12 and 13)
The protein expressions of HO-1, NQO-1, and GPx, three
indicators of anti-oxidative activities, were not lowest in
group 2, and significantly lower in group 1 than that in
groups 3 and 4, but it displayed no difference between
groups 3 and 4 at 24 h and 72 after IR procedure
(Figure 12A-F).
The protein expressions of catalase and SOD-1, two
scavengers of superoxide, were lowest in group 1 andhighest in group 4, and significantly higher in group 3
than that in group 2 after the two intervals of reperfusion
(Figure 13). In addition, the protein expression of eNOS,
an indicator of anti-inflammation, was significantly higher
in group 1 than that in other groups, significantly higher
in groups 3 and 4 than that in group 2, but it showed no
difference between groups 3 and 4 after these two time
intervals (Figure 13A-F).
Discussion
The present study, which investigated the therapeutic effect
of sitagliptin and exendin-4 against acute renal IR injury,
yielded several conspicuous implications.
First, exendin-4 was comparable to sitagliptin in attenu-
ating the architectural integrity of renal parenchyma and
arresting the deterioration of renal function after IR injury.
Second, either drug remarkably suppressed IR-induced
acute kidney injury via inhibiting IR-triggered macrophage
Figure 7 Changes in protein expressions of tumor necrotic factor (TNF)-α, nuclear factor (NF)-κB and intercellular adhesion molecule
(ICAM)-1 in kidney at 24 h and 72 h after ischemia-reperfusion (IR) procedure (n = 6 at each time for each group). A and B) The
analytical results of TNF-α protein expression in kidney parenchyma at 24 h (A) and 72 h (B) after IR procedure. * vs. other groups with different
symbols (*, †, ‡), p < 0.01 at 24 h and 72 h, respectively. C and D) The analytical results of NF-κB protein expression in kidney parenchyma at 24 h
(C) and 72 h (D) after IR procedure. * vs. other groups with different symbols (*, †, ‡), p < 0.001 at 24 h and 72 h, respectively. E and F) The
analytical results of ICAM-1 protein expression in kidney parenchyma at 24 h (E) and 72 h (F) after IR procedure. * vs. other groups with different
symbols (*, †, ‡), p < 0.01 at 24 h and 72 h, respectively. All statistical analyses were with one-way ANOVA followed by Bonferroni multiple
comparison post hoc test. Symbols (*, †, ‡) indicate significance at the 0.05 level. SC = sham control; IR = ischemia-reperfusion;
Sita = sitagliptin; Ex-4 = extendin-4.
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and ROS generation, as well as through attenuating
cellular apoptotic signaling pathway and enhancing
GLP-1R expression and anti-oxidant factors in renal
parenchyma. Third, to the best of our knowledge, thisis the first study to demonstrate the benefits of sitagliptin
and exendin-4 in protecting the kidneys from acute
IR injury other than their therapeutic actions against
hyperglycemia. Of importance is the fact that the results
were promising.
Figure 8 Changes in protein expressions of NOX-1 and NOX-2 in kidney at 24 h and 72 h after ischemia-reperfusion (IR) procedure
(n = 6 at each time for each group). A and B) The analytical results of NOX-1 protein expression in kidney parenchyma at 24 h (A) and 72 h
(B) after IR procedure. * vs. other groups with different symbols (*, †, ‡), p < 0.01 at 24 h and 72 h, respectively. C and D) The analytical results of
NOX-2 protein expression in kidney parenchyma at 24 h (C) and 72 h (D) after IR procedure. * vs. other groups with different symbols (*, †, ‡),
p < 0.01 at 24 h and 72 h, respectively. All statistical analyses were with one-way ANOVA followed by Bonferroni multiple comparison post hoc
test. Symbols (*, †, ‡) indicate significance at the 0.05 level. SC = sham control; IR = ischemia-reperfusion; Sita = sitagliptin; Ex-4 = extendin-4.
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attenuating IR-induced acute kidney injury--– functional
assay and pathological findings
The most distinctive finding in the current study is that
the serum BUN and creatinine levels, two important
indices of kidney function, were remarkably elevated in
animals after acute renal IR injury than those in sham
controls. The increases of these parameters were signifi-
cantly suppressed after sitagliptin or exendin-4 treatment.
One important finding is that the ratio of urine protein to
creatinine, a useful indicator of impaired renal function,
was markedly increased in animals after acute kidney IR
compared to that in the sham controls at 24 hr and 72 hr
after the procedure. IR-induced elevation of this para-
meter was significantly suppressed by either sitagliptin or
exendin-4 treatment. Another noteworthy finding in the
present study is that the histopathological renal injury
scores were significantly higher in animals after renal IR
than those in sham controls at the two time points, butwere significantly reduced by either sitagliptin or exendin-4
therapy. Importantly, this study is the first to demonstrate
the therapeutic actions of sitagliptin and exendin-4 in
protecting the kidney against acute IR injury other than
their roles as hypoglycemic agents. Moreover, the results of
the present study also demonstrated comparable protection
offered by the two drugs.
Protection against acute renal IR injury through
attenuation of inflammation
Previous studies have shown that ischemia or IR elicits
tremendous inflammatory response [20,22,38]. In addition,
the initiation and propagation of inflammatory reaction
are major contributors to tissue/organ damage after acute
IR injury [20,22,38]. One essential finding in the present
study is the augmentation the expressions of inflammatory
biomarkers at cellular (i.e., macrophage), gene (i.e., MMP-9,
IL-1β, TNF-α, PAI-1), and protein (i.e., TNF-α, NF-κB,
ICAM-1) levels in kidney parenchyma in the IR animals
Figure 9 Changes in protein expressions of oxidative stress in kidney at 24 and 72 h after ischemia-reperfusion (IR) procedure (n = 6 at each
time for each group). A and B) Protein expression of oxidative index (protein carbonyls) in kidney parenchyma among four groups of animals at 24 h
(A) and 48 h (B) after IR procedure. * vs. other groups with different symbols (*, †, ‡), p < 0.001 at 24 h and 72 h, respectively. (Note: Right lane and left
lane shown on the upper panel represent control oxidized molecular protein standard and protein molecular weight marker, respectively). DNP = 1–3
dinitrophenylhydrazone. All statistical analyses were with one-way ANOVA followed by Bonferroni multiple comparison post hoc test. Symbols (*, †, ‡)
indicate significance at the 0.05 level. SC = sham control; IR = ischemia-reperfusion; Sita = sitagliptin; Ex-4 = extendin-4.
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at 24 hr, but also at 72 hr after reperfusion. Accordingly,
our findings are consistent with those of previous studies
[20,22,38]. Of importance is the fact that these inflam-
matory biomarkers were markedly suppressed in the IR
animals after receiving sitagliptin or exendin-4 treatment.
In this way, our findings further reinforce those of previous
studies that also reported the link between the reduction of
inflammatory reaction and the preservation of functional
integrity of the kidney after ischemia/IR injury [20,38].
Fascinatingly, the expressions of anti-inflammatory
biomarkers at gene (IL-10, eNOS) and protein (eNOS)
levels were notably enhanced in IR animals after sitagliptin
and exendin-4 treatment, highlighting the intrinsic anti-
inflammatory properties of the two agents other than their
hypoglycemic actions. Therefore, our findings could, at
least in part, explain the notably aggravated renal histo-
logical distortion and dysfunction in the setting of acutekidney IR and also the mechanisms by which sitagliptin
and exendin-4 suppressed the renal IR-induced damage.
Protection against acute renal IR injury through reduction
of oxidative stress
The generation of oxidative stress and ROS have also been
shown to play a crucial role in acute kidney IR injury
[11,15,20,23-27,39]. The principal finding in the present
study is the markedly enhanced protein expressions of oxi-
dative stress (i.e., oxidized protein) and ROS (i.e., NOX-1,
NOX-2) in renal parenchyma of animals following acute
kidney IR compared to those in the sham controls at both
24 hr and 72 hr after reperfusion. However, the expressions
of these biomarkers were notably suppressed in IR animals
after receiving either sitagliptin or exendin-4 treatment. Of
importance is that the expressions of the anti-oxidative
markers at protein level (HO-1, NQO-1, GPx-1, catalase,
SOD) was significantly upregulated in the IR animals
Figure 10 Changes in protein expressions of apoptotic biomarkers in kidney at 24 and 72 h after ischemia-reperfusion (IR) procedure
(n = 6 at each time for each group). A and B) Protein expression of mitochondrial (Mito) Bax at 24 h (A) and 72 h (B) after acute IR procedure.
* vs. other groups with different symbols (*, †, ‡), p < 0.01 at 24 h and p < 0.001 at 72 h, respectively. C and D) Protein expression of cleaved poly
(ADP-ribose) polymerase (c-PARP) at 24 h (C) and 72 h (D) after acute IR procedure. * vs. other groups with different symbols (*, †, ‡), p < 0.01 at
24 h and p < 0.001 at 72 h, respectively. E and F) Protein expression of cleaved caspase (c-Csp3) 3 at 24 h (E) and 72 h (D) after acute IR
procedure. * vs. other groups with different symbols (*, †, ‡), p < 0.01 at 24 h and p < 0.001 at 72 h, respectively. All statistical analyses were with
one-way ANOVA followed by Bonferroni multiple comparison post hoc test. Symbols (*, †, ‡) indicate significance at the 0.05 level. SC = sham
control; IR = ischemia-reperfusion; Sita = sitagliptin; Ex-4 = extendin-4.
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pared to those without. Beside their well-known roles
as hypoglycemic agents, GLP-1 analogues (including
exendin-4) have been reported to possess both anti-
oxidative properties [29-31] and anti-inflammatory [31-33]
properties. Moreover, sitagliptin, an oral hyperglycemicagent, has been found to be capable of enhancing circu-
lating GLP-1 levels via suppressing DPP-IV activity
[35,36], thereby contributing to its anti-inflammatory
and anti-atherosclerotic cardiovascular protective effect [37].
Our findings, therefore, in addition to being supported
by the previous studies [29-37], could further explain
Figure 11 Changes in protein expressions of Bcl-2 and γH2AX in kidney at 24 and 72 h after ischemia-reperfusion (IR) procedure
(n = 6 at each time for each group). A and B) The protein expression of Bcl-2 at 24 h (A) and 72 h (B) after acute IR procedure. * vs. other
groups with different symbols (*, †, ‡), p < 0.001 at 24 h and 72 h, respectively. C and D) The protein expression of γH2AX at 24 h (C) and 72 h
(D) after acute IR procedure. * vs. other groups with different symbols (*, †, ‡), p < 0.01 at 24 h and p < 0.001 at 72 h, respectively. All statistical
analyses were with one-way ANOVA followed by Bonferroni multiple comparison post hoc test. Symbols (*, †, ‡) indicate significance at the 0.05
level. SC = sham control; IR = ischemia-reperfusion; Sita = sitagliptin; Ex-4 = extendin-4.
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acute renal IR injury.
Protection against acute renal ir injury through
suppression of cellular apoptosis and DNA damage
Inevitably, cellular apoptosis always takes place after
acute ischemia/IR injury [21,38,39]. An association between
cellular apoptosis and organ dysfunction has long been
identified by experimental studies [21,38,39]. An important
finding in the present study is the significantly elevated
protein expressions of apoptotic (i.e., cleaved caspase 3
and PARP, mitochondrial Bax) and DNA damage (i.e.,
γ-H2AX) biomarkers in renal parenchyma of IR animals
compared to those in the sham controls at both 24 hr and
72 hr following reperfusion. In this way, our findings cor-
roborated those of previous studies [21,38,39]. However,
these biomarkers were substantially reduced in the kidney
parenchyma of IR animals after receiving either sitagliptin
or exendin-4 treatment. Besides, the protein expressionof the anti-apoptotic biomarker, i.e., Bcl-2, was notably
augmented after treatment with either agent. Our findings
could partially account for the suppressed IR-induced renal
histopathological damage after treatment with sitagliptin
and extendin-4.
Protection against acute renal IR injury through
enhancing circulating GLP-1 level and GLP-1R expression
in renal parenchyma
Although the distribution of GLP-1 binding sites (i.e., GLP-
1R) in the central nervous system and the peripheral
autonomic nervous system has been extensively investi-
gated in previous studies [40-45], the expression of
GLP-1R in renal parenchyma has not been reported. One
interesting finding in the current study is the significantly
higher circulating GLP-1 level in IR animals with and
without exendin-4 treatment than that in the sham
controls and also the highest level in IR animals receiving
sitagliptin treatment. This may be the result of stress
Figure 12 Changes in protein expressions of anti-oxidant biomarkers in kidney at 24 and 72 h after ischemia-reperfusion (IR)
procedure (n = 6 at each time for each group). A and B) The protein expression of heme oxygenase (HO)-1 at 24 h (A) and 72 h (B) after
acute IR procedure. * vs. other groups with different symbols (*, †, ‡), p < 0.001 at 24 h and 72 h, respectively. C and D) The protein expression of
NAD(P)H quinone oxidoreductase (NQO)-1 at 24 h (C) and 72 h (D) after acute IR procedure. * vs. other groups with different symbols (*, †, ‡),
p < 0.001 at 24 h and 72 h, respectively. E and F) The protein expression of Glutathione peroxidase (GPx) at 24 h (E) and 72 h (F) after acute IR
procedure. * vs. other groups with different symbols (*, †, ‡), p < 0.001 at 24 h and 72 h, respectively. All statistical analyses were with one-way
ANOVA followed by Bonferroni multiple comparison post hoc test. Symbols (*, †, ‡) indicate significance at the 0.05 level. SC = sham control;
IR = ischemia-reperfusion; Sita = sitagliptin; Ex-4 = extendin-4.
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of GLP-1 from the digestive system. Additionally, the
highest circulating level of GLP-1 after sitagliptin treatment
could be due to the inhibitory effect of sitagliptin on the
enzymatic activity of DDP-IV which has been found tocleave GLP-1 in the circulation [35,36]. The novel finding
in the present study is that, under normal situation, GLP-1
binding sites were rare in the kidney parenchyma as shown
in immunohistochemical staining and western blotting.
However, during acute kidney IR injury, the expression
Figure 13 Changes in protein expressions of anti-superoxide and anti-inflammatory biomarkers in kidney at 24 and 72 h after
ischemia-reperfusion (IR) procedure (n = 6 at each time for each group). A and B) The protein expression of superoxide dismutase (SOD)-1
at 24 h (A) and 72 h (B) after IR procedure. * vs. other groups with different symbols (*, †, ‡), p < 0.001 at 24 h and 72 h, respectively. C and D)
The protein expression of catalse at 24 h (C) and 72 h (D) after IR procedure. * vs. other groups with different symbols (*, †, ‡), p < 0.001 at 24 h
and 72 h, respectively. E and F) The protein expression of endothelial nitric oxide synthase (eNOS) at 24 h (E) and 72 h (F) after IR procedure.
* vs. other groups with different symbols (*, †, ‡), p < 0.001 at 24 h and 72 h, respectively. All statistical analyses were with one-way ANOVA followed
by Bonferroni multiple comparison post hoc test. Symbols (*, †, ‡) indicate significance at the 0.05 level. SC = sham control; IR = ischemia-reperfusion;
Sita = sitagliptin; Ex-4 = extendin-4.
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markedly enhanced in the kidney parenchyma. The other
novel and interesting finding (i.e., IHC staining result) is
the predominant distribution of GLP-1 binding sites in
the both glomeruli and renal tubules.Another distinctive finding is that the protein expression
of GLP-1 binding sites in kidney parenchyma was rare in
normal condition that was only markedly augmented after
acute IR injury. Of particularly distinctive finding was that
the expression of this biomarker in renal parenchyma was
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ment than in IR animals without treatment and further
significantly higher in IR animals after receiving exendin-4
treatment. These findings suggest an automatic up-regu-
lating expression of GLP-1 binding sites in IR animals
after both drug treatment. Of importance is that these
findings (i.e., circulating GLP-1 and GLP-1 binding sites
in kidney parenchyma) not only were consistent with our
hypothesis, but also provided a good positive correlation
between the up-regulated expression of GLP-1 binding
sites and suppressing the generations of inflammation,
oxidative stress, and ROS in the present study.
Study limitations
This study has several limitations. First, we remain uncer-
tain regarding the explanation of the finding that exendin-4
had relatively higher potency than that of sitagliptin in
suppressing kidney injury score and inflammatory cellsFigure 14 Proposed mechanisms underlying the positive therapeutic eff
injury. GLP-1R = glucagon-like peptide-1 receptor; TNF = tumor necrotic factor
activator inhibitor; NF = nuclear factor; ICAM= intercellular adhesion molecule;
NQO=NAD(P)H quinone oxidoreductase; GPx = glutathione peroxidase; NOX =
polymerase; BUN = blood urine nitrogen.(CD68+) and in up-regulating the expressions of GLP-1R
and anti-oxidants (SOD, catalase). This is perhaps due to
the fact that exendin-4, a GLP-1 analogue, possess stron-
ger anti-oxidative [29-31] and anti-inflammatory [31-33]
properties compared to those of sitagliptin. Second, despite
extensive investigation in the current study, the precise sig-
naling pathway(s) through which sitagliptin and exendin-4
exert their therapeutic effects have not been elucidated.
We have, however, proposed the mechanisms based on the
findings of the current study as summarized in Figure 14.
Third, although the rationale of using sitagliptin and
exendin-4 was elucidated in the present study, we did not
test the potential toxicity of these two drugs in the setting
of acute renal injury. In fact, the dosage of sitagliptin has
been recommended to be reduced by half if the patient's
estimated glomerular filtration rate (eGFR) is < 30 mL/
min/1.73 m2. Therefore, the regimen dosage of this
study is not recommended to extrapolate to humankindects of sitagliptin and exendin-4 on kidney ischemia-reperfusion (IR)
; MMP =matrix metalloproteinase; IL = interleukin; PAI = plasminogen
eNOS = endothelial nitric oxide synthase; HO = heme oxygenase;
ADPH oxidase; SOD = superoxide dismutase; PARP = poly(ADP-ribose)
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athy, shock followed by resuscitation in the emergency
and intensive care, kidney transplantation, sepsis or
cardiovascular surgery.
In conclusion, acute kidney IR injury significantly
augmented GLP-1R expression in kidney parenchyma
that were further augmented after sitagliptin or exendin-4
therapy. Either sitagliptin or exendin-4 treatment effectively
protected the kidney from IR injury through the suppres-
sion of inflammatory reaction, apoptosis, oxidative stress in
a rodent model of renal IR injury.
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